Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma

A prospective multicenter study

Ki Seong Eom, Seok Jin Kim, Je Jung Lee, Cheolwon Suh, Jinseok Kim, Sung Soo Yoon, Byung Soo Kim, Hye Jin Kang, Young Jin Choi, Chul Soo Kim, Yang Soo Kim, Jae Yong Kwak, Yoo Jin Kim, Young Don Joo, Yeung Chul Mun, Deog Yeon Jo, Joon Seong Park, Chi Young Park, Sung Hyun Kim, Chang Ki Min

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced disease (n = 89). Among them, 75 patients completed 4 cycles of treatment. Most of the patients (81.7%) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%). The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90% after the 8th cycle. DKK-1 levels decreased significantly posttreatment. Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P = 0.037). In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.

Original languageEnglish
Article number245247
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Multiple Myeloma
Multicenter Studies
Osteoprotegerin
Bone
Steroids
Prospective Studies
Plasmas
Osteoblasts
Refractory materials
Therapeutics
Osteoclasts
Osteogenesis
Bortezomib
Bone Remodeling
Bone Resorption

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Eom, Ki Seong ; Kim, Seok Jin ; Lee, Je Jung ; Suh, Cheolwon ; Kim, Jinseok ; Yoon, Sung Soo ; Kim, Byung Soo ; Kang, Hye Jin ; Choi, Young Jin ; Kim, Chul Soo ; Kim, Yang Soo ; Kwak, Jae Yong ; Kim, Yoo Jin ; Joo, Young Don ; Mun, Yeung Chul ; Jo, Deog Yeon ; Park, Joon Seong ; Park, Chi Young ; Kim, Sung Hyun ; Min, Chang Ki. / Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma : A prospective multicenter study. In: BioMed Research International. 2014 ; Vol. 2014.
@article{e04112815d214e0d918512cf2b1cbd6d,
title = "Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study",
abstract = "We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced disease (n = 89). Among them, 75 patients completed 4 cycles of treatment. Most of the patients (81.7{\%}) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4{\%}), while 26 patients achieved less than PR (35.6{\%}). The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90{\%} after the 8th cycle. DKK-1 levels decreased significantly posttreatment. Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P = 0.037). In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.",
author = "Eom, {Ki Seong} and Kim, {Seok Jin} and Lee, {Je Jung} and Cheolwon Suh and Jinseok Kim and Yoon, {Sung Soo} and Kim, {Byung Soo} and Kang, {Hye Jin} and Choi, {Young Jin} and Kim, {Chul Soo} and Kim, {Yang Soo} and Kwak, {Jae Yong} and Kim, {Yoo Jin} and Joo, {Young Don} and Mun, {Yeung Chul} and Jo, {Deog Yeon} and Park, {Joon Seong} and Park, {Chi Young} and Kim, {Sung Hyun} and Min, {Chang Ki}",
year = "2014",
month = "1",
day = "1",
doi = "10.1155/2014/245247",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

Eom, KS, Kim, SJ, Lee, JJ, Suh, C, Kim, J, Yoon, SS, Kim, BS, Kang, HJ, Choi, YJ, Kim, CS, Kim, YS, Kwak, JY, Kim, YJ, Joo, YD, Mun, YC, Jo, DY, Park, JS, Park, CY, Kim, SH & Min, CK 2014, 'Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study', BioMed Research International, vol. 2014, 245247. https://doi.org/10.1155/2014/245247

Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma : A prospective multicenter study. / Eom, Ki Seong; Kim, Seok Jin; Lee, Je Jung; Suh, Cheolwon; Kim, Jinseok; Yoon, Sung Soo; Kim, Byung Soo; Kang, Hye Jin; Choi, Young Jin; Kim, Chul Soo; Kim, Yang Soo; Kwak, Jae Yong; Kim, Yoo Jin; Joo, Young Don; Mun, Yeung Chul; Jo, Deog Yeon; Park, Joon Seong; Park, Chi Young; Kim, Sung Hyun; Min, Chang Ki.

In: BioMed Research International, Vol. 2014, 245247, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma

T2 - A prospective multicenter study

AU - Eom, Ki Seong

AU - Kim, Seok Jin

AU - Lee, Je Jung

AU - Suh, Cheolwon

AU - Kim, Jinseok

AU - Yoon, Sung Soo

AU - Kim, Byung Soo

AU - Kang, Hye Jin

AU - Choi, Young Jin

AU - Kim, Chul Soo

AU - Kim, Yang Soo

AU - Kwak, Jae Yong

AU - Kim, Yoo Jin

AU - Joo, Young Don

AU - Mun, Yeung Chul

AU - Jo, Deog Yeon

AU - Park, Joon Seong

AU - Park, Chi Young

AU - Kim, Sung Hyun

AU - Min, Chang Ki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced disease (n = 89). Among them, 75 patients completed 4 cycles of treatment. Most of the patients (81.7%) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%). The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90% after the 8th cycle. DKK-1 levels decreased significantly posttreatment. Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P = 0.037). In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.

AB - We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced disease (n = 89). Among them, 75 patients completed 4 cycles of treatment. Most of the patients (81.7%) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%). The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90% after the 8th cycle. DKK-1 levels decreased significantly posttreatment. Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P = 0.037). In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.

UR - http://www.scopus.com/inward/record.url?scp=84904129518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904129518&partnerID=8YFLogxK

U2 - 10.1155/2014/245247

DO - 10.1155/2014/245247

M3 - Article

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 245247

ER -